4.8 Editorial Material

Diagnostic preparedness for infectious disease outbreaks

期刊

LANCET
卷 390, 期 10108, 页码 2111-2114

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(17)31224-2

关键词

-

资金

  1. GlaxoSmithKline
  2. PATH's Malaria Vaccine Initiative
  3. Optimus Foundation
  4. Novartis Institute of Tropical Diseases
  5. Bill & Melinda Gates Foundation
  6. MVI

向作者/读者索取更多资源

Diagnostics are crucial in mitigating the effect of disease outbreaks. Because diagnostic development and validation are time consuming, they should be carried out in anticipation of epidemics rather than in response to them. The diagnostic response to the 2014-15 Ebola epidemic, although ultimately effective, was slow and expensive. If a focused mechanism had existed with the technical and financial resources to drive its development ahead of the outbreak, point-of-care Ebola tests supporting a less costly and more mobile response could have been available early on in the diagnosis process. A new partnering model could drive rapid development of tests and surveillance strategies for novel pathogens that emerge in future outbreaks. We look at lessons learned from the Ebola outbreak and propose specific solutions to improve the speed of new assay development and ensure their effective deployment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据